The frontline drugs for malaria — artemisinin-based combination therapies — have held for decades, but a growing body of genetic evidence suggests that window may be narrowing. Understanding precisely where resistance is emerging versus spreading across Africa could determine whether public health systems can contain it or will be overwhelmed by it. This large-scale analysis arrives at a critical juncture for global malaria control.
This systematic review and spatiotemporal modelling study, published in The Lancet Infectious Diseases, synthesized data from PubMed, MEDLINE, and Web of Science alongside 11 unpublished datasets and major genomic repositories including MalariaGEN Pf8, WWARN's molecular surveyor, and the WHO malaria threats map. The combined dataset tracked genotyping of kelch13 (k13) mutations — the primary genetic markers of artemisinin partial resistance — as well as mdr1 N86Y and crt K76T mutations, which signal reduced susceptibility to ACT partner drugs such as lumefantrine and amodiaquine. The resulting high-resolution spatiotemporal maps modelled resistance prevalence across African sub-regions over the decade following 2014.
The critical public health question the study attempts to answer — whether rising k13 prevalence reflects independent local emergence or geographic spread from established foci — has profound implications. Independent emergence suggests widespread selective pressure from drug use; geographic expansion implies that a resistant clone, analogous to the Southeast Asian kelch13 mutant lineages that devastated regional malaria control, may be propagating across the continent. Artemisinin partial resistance was first confirmed in Africa, particularly in Rwanda and Uganda, around 2020, and the pace of subsequent reports has unsettled malaria researchers. This study's modelling framework represents a meaningful methodological advance over prior point-prevalence estimates, though spatiotemporal models carry inherent uncertainty in data-sparse regions. The practical consequence for adults in endemic regions and for global health investment decisions is significant: if partner-drug resistance is co-evolving alongside artemisinin resistance, the entire ACT architecture faces simultaneous pressure, with few credible therapeutic alternatives currently scaled for mass deployment.